Clinical trials in metastatic prostate cancer – Has there been real progress in the past decade?
- 1 April 2005
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (6) , 941-953
- https://doi.org/10.1016/j.ejca.2005.02.008
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- Endothelin Inhibition: Novel Therapy for Prostate CancerJournal of Urology, 2003
- Treatments for Improving Survival of Patients with Prostate CancerDrugs & Aging, 2003
- Combination Chemotherapy with Paclitaxel, Estramustine and Carboplatin for Hormone Refractory Prostate CancerJournal of Urology, 2002
- Vinorelbine in androgen-independent metastatic prostatic carcinoma—a phase II studyEuropean Journal Of Cancer, 2002
- Weekly docetaxel and estramustine in patients with hormonerefractory prostate cancerSeminars in Oncology, 2001
- N-Methylated Cyclic RGD Peptides as Highly Active and Selective αVβ3Integrin AntagonistsJournal of Medicinal Chemistry, 1999
- Role of integrins in angiogenesisEuropean Journal Of Cancer, 1996
- High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary GroupEuropean Journal Of Cancer, 1995
- Suramin: A new therapeutic conceptEuropean Journal of Cancer and Clinical Oncology, 1990
- Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.The Journal of cell biology, 1988